Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19

GENERAL INFORMATION

Eligibility criteria for nirmatrelvir/ritonavir has been expanded

Various agents are available in BC for the treatment of COVID-19 in mildly-moderately ill patients. These therapies include a monoclonal a direct-acting oral antiviral nirmatrelvir/ritonavir (Paxlovid) and an IV antiviral, remdesivir (Veklury). A monoclonal antibody (mAB) sotrovimab (Xevudy) has also been shown efficacious in treating mild-moderate illness; however, it has reduced activity against the BA.2 variant. Finally, another oral antiviral, molnupiravir (Lagevrio) is currently being considered for Health Canada approval. These four agents have added to the armamentarium of previously available repurposed therapies (inhaled steroids, fluvoxamine, colchicine). This document provides general recommendations for the use of these therapeutics and supporting evidence, with additional practice tools available separately. See Toolkit #1 – Step-by-step Assessment for practical prescribing information.

This April 12th update serves provide updated recommendations pertaining to the BA.2 variant.

RECOMMENDATIONS

Complete expanded eligibility for nirmatrelvir/ritonavir (Paxlovid) includes:

- Immunocompromised individuals¹,² and those with high-risk conditions³ identified as Clinically Extremely Vulnerable Group 1¹, Group 2², and Group 3³ (CEV 1, CEV 2, and CEV 3), regardless of vaccine status or previous infection. (See also Practice Tool 2 – CEV Definitions).

- Unvaccinated individuals without previous infection who are EITHER:
  - ≥50 years OR
  - have three or more chronic conditions/co-morbidities*

- Individuals ≥ 50 years with 1-2 vaccine doses or previous infection alone, with three or more chronic conditions/co-morbidities*

- Individuals aged ≥70 years with 1-2 vaccine doses or previous infection alone, with one or more chronic condition/co-morbidity*

- Individuals ≥ 70 years with three or more chronic conditions/co-morbidities*, regardless of vaccine status or previous infection

- Indigenous individuals (if not captured above) who are EITHER:
  - unvaccinated without previous infection OR
  - ≥ 50 years with 1-2 vaccine doses or with previous infection alone OR
  - ≥ 70 years regardless of vaccine status or previous infection
**Chronic conditions include e.g.: obesity, smoking, diabetes, heart failure, heart disease, stroke, neurological conditions**

1. **CEV 1:** severe immunocompromise due to, e.g., solid organ transplant, bone marrow or stem cell transplant, treatment for hematological malignancy, receiving anti-CD20 or B-cell depleting therapies
2. **CEV 2:** moderate immunocompromise due to e.g., receiving immunosuppressive agents, moderate-severe primary immunodeficiency, cancer treatment for solid tumors, advanced or untreated HIV
3. **CEV 3:** e.g., cystic fibrosis, severe asthma or COPD, diabetes requiring insulin, intellectual and developmental disabilities, rare blood disorders, dialysis, neurological conditions requiring Bi-PAP or chronic ventilation, cancer not captured above

**Therapy Recommendations**

<table>
<thead>
<tr>
<th>Therapy Recommendation</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Nirmatrelvir/ritonavir 300/100mg PO BID x 5 days**                                    | (150/100mg PO BID x 5 days in eGFR 30-60ml/min) is **recommended** within 5 days* of symptom onset to patients with a **5% or greater risk**^ for hospitalization or progression to severe COVID-19
   | OR, if nirmatrelvir/ritonavir cannot be given to patients with a 5% or greater risk due to drug-drug interactions or contraindications (See Practice Tool 3 – Drug Interactions and Contraindications) |
| **Remdesivir 200mg IV on day 1, followed by 100mg IV on days 2 and 3**                  | (200mg IV on day 1, followed by 100mg IV 48-72 hours later in eGFR <30ml/min) is **recommended** within 7 days of symptom onset as an alternative to nirmatrelvir/ritonavir |
| **Nirmatrelvir/ritonavir 300/100mg PO BID x 5 days**                                    | (150/100mg PO BID x 5 days in eGFR 30-60ml/min) is **suggested** within 5 days of symptom onset to patients with a **3-4% risk**^ of hospitalization or progression to severe COVID-19. As treatment effect is not directly known in this population, the estimated benefit needs to be weighed against potential risk of adverse effects in consideration with patient’s values and preferences
| **Due to a limited drug supply, operational constraints and unclear benefit in lower risk individual, patients with a risk of 5% or greater are currently being prioritized and offered treatment with remdesivir.** |

^To quantify the risk based on patient factors, see Risk Assessment and Local Data below

*The symptom window can be extended to 7 days in patients with a 5% or greater risk if they would otherwise be referred for remdesivir solely based on its longer treatment window

**THERE IS NO INDICATION TO COMBINE THESE THERAPIES:** Due to drug scarcity and limited additional benefit, patients should receive ONE COVID-19-specific therapy.

**Sotrovimab** has demonstrated reduced neutralization against the BA.2 variant although it may retain some activity. If sotrovimab is used as a last line agent where potential of benefit outweighs the risk, disclosure to patients of risks and benefits in consideration of individual circumstances (clinical status, patient values, logistics) is necessary. Sotrovimab should not be chosen solely for convenience reasons.
### Molnupiravir

**800mg PO BID x 5 days is not routinely recommended** *(if/once available in Canada)*; if used on a case-by-case basis in patients who are unable to receive nirmatrelvir/ritonavir, sotrovimab or remdesivir, the uncertainty of benefit and the absolute risk of hospitalization, including factors such as age, number and type of co-morbidities and severity of symptoms need to be considered.

### Inhaled Budesonide

**800 μg twice daily for 14 days** may be considered on a case-by-case basis in patients who have lower respiratory tract symptoms (cough, shortness of breath) for symptom relief. There is no evidence of additional benefit of inhaled steroids to antivirals or antibody therapy.

### Colchicine

*not recommended* due to low certainty of benefit and potential risk of adverse events and additional immunosuppression in this population.

### Fluvoxamine

*not recommended* due to low certainy of benefit and potential risk of adverse events associated with the dose evaluated (100mg PO BID), especially in vulnerable and elderly patients.

## PRACTICAL CONSIDERATIONS

### Risk Assessment

Single variable criteria (e.g., age only) identify patients who have a wide range of risk and are imprecise. Priority criteria for this guide were developed utilizing provincial multi-variable modelling to identify patients who would benefit most from treatment using age, vaccine status and type and number of co-existing chronic conditions/co-morbidities. An additional study was undertaken to exclude patients who were hospitalized but diagnosed with COVID-19 incidentally.

Patients who are likely to have a clinically meaningful reduction in hospitalization are those who have a risk of hospitalization of at least 3% from Omicron. Such patients were selected to be eligible for therapy; however, **patients who are most likely to benefit based on evidence from clinical trials are those with a risk of ≥ 5%**. Such patients are eligible to receive nirmatrelvir/ritonavir, and if contraindications or drug-drug interactions prohibit administration, remdesivir as an alternative. Those who have a slightly elevated risk from average (3-4%) are eligible for nirmatrelvir/ritonavir, but the paucity of data that informs the magnitude of benefit and the balance between risk vs. potential benefit needs to be acknowledged and incorporated into the decision to treat. Currently, patients with a risk of ≥5% are prioritized for remdesivir.

Risk can be estimated using a scoring system below. The scoring system accurately predicts the risk category from the BC-specific analysis 98% of the time and is 100% concordant with the CTC overall eligibility criteria.

Within these point categories, however, the absolute risk still varies. Even within the highest-risk priority group, a wide range of risk exists; risk increases by age number of comorbidities and incomplete vaccination status. Each additional chronic condition/co-morbidity also increases risk. This document provides guidance only; **patients defined above or those who score 4 or more points are those who may benefit from treatment – case-by-case assessment is still required, and the totality of risk factors needs to be considered when offering treatment.** This risk is conservative and likely overestimated.
Clinical Practice Guide for Therapeutics in Patients with Mild-Moderate COVID-19: April 12, 2022

**Legend: Estimated Hospitalization Risk**

- **3 points or less**: No increased risk; treatment is not recommended
- **4 points**: Slightly increased risk (3-4%); treatment is suggested
- **5 points**: Increased risk (5-9%); treatment is recommended
- **6 points or more**: Highest risk (≥ 10%); treatment is recommended

*Chronic conditions include e.g., obesity, smoking, diabetes, heart failure, heart disease, stroke

1. **CEV 1**: Severe immunocompromise due to, e.g., solid organ transplant, bone marrow or stem cell transplant, treatment for hematological malignancy, receiving anti-CD20 or B-cell depleting therapies
2. **CEV 2**: Moderate immunocompromise due to e.g., receiving immunosuppressive agents, moderate-severe primary immunodeficiency, treatment for solid tumors, advanced HIV
3. **CEV 3**: e.g., cystic fibrosis, severe asthma or COPD, diabetes requiring insulin, intellectual and developmental disabilities, rare blood disorders, dialysis, neurological conditions requiring Bi-PAP/chronic ventilation, cancer not captured above

---

**Point Scoring to Estimate Hospitalization Risk**

<table>
<thead>
<tr>
<th>Age (select ONE)</th>
<th>Point Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>70+</td>
<td>2</td>
</tr>
<tr>
<td>50-69</td>
<td>1</td>
</tr>
<tr>
<td>&lt;50</td>
<td>0</td>
</tr>
</tbody>
</table>

**Vaccine Status (select ONE)**

- Unvaccinated AND no previous infection: 3 points
- Vaccinated with 1 or 2 doses OR previous infection alone: 1 point
- Vaccinated with booster (3 doses) OR previous infection + any vaccination: 0 points

**At-Risk Conditions (select ONE with the highest value)**

- **CEV 1** (Severe Immunocompromise): 6 points
- **CEV 2 or CEV 3**: 4 points
- Indigenous: 2 points
- 3+ chronic conditions/comorbidities: 2 points
- 1-2 chronic conditions/comorbidities: 1 point
- no chronic conditions: 0 points

Add the points from the three sections

---

**Local Data and Risk Models**

Therapies recommended in this guide were evaluated in the pre-Omicron wave; variants of concern (VoCs) in trials included predominantly Delta, with other VoCs comprising a small fraction of sequenced virus. Nirmatrelvir/ritonavir, remdesivir and sotrovimab were shown to reduce the risk of disease progression (i.e., hospitalization or development of severe COVID-19) from about 6% to about 1%, for a relative risk reduction of ~85%, an absolute risk reduction of 5% and a number-needed-to-treat of ~20.

During the Omicron wave, the risk of hospitalization in BC has decreased drastically to 1.2% from 6.3% in the preceding period. As such, patients who are offered treatment need to be carefully selected for therapy to yield clinically meaningful reductions in hospitalizations. While nirmatrelvir/ritonavir and remdesivir retain full pharmacological activity against Omicron, sotrovimab has greatly reduced binding against BA.2 and full efficacy cannot be inferred. Furthermore, a study conducted in partnership with the BCCDC showed that a large proportion of hospitalizations in COVID-infected patients were not FOR COVID-19 but rather WITH COVID-19, i.e., the infections were incidentally diagnosed and were not the cause for about 60% of the hospitalizations. Finally, these models overestimate the risk as they do not capture patients who were asymptomatic or who did not receive PCR testing; the actual risk is lower.
The CTC has partnered with HSIAR, the BCCDC and other epidemiology research groups to characterize risk from Omicron in BC, and show how age, vaccine status and at-risk conditions influence the risk.

Thermal Map of Hospitalization Risk from Omicron, excluding incidental diagnoses (Jan-Feb)

Please note that not all cells in the thermal maps are concordant with recommendations; general trends and other data were used.

The CTC would like to credit Kate Smolina and Christopher Mills and their team from the BCCDC and Heather Richards and her team from the HSAIR at the Ministry of Health for data and models provided in this guidance.

Clinically Vulnerable Patients
Patients categorized as CEV Group 1 have the highest risk of hospitalization, requiring ICU-level care and death; although the receipt of 3 or more doses (achieved in >80% of this population) mitigates this risk, they still experience hospitalizations rates of over 10% especially if elderly. Incidental COVID is also less likely in this population. Patients in CEV Group 2 and Group 3 have a lower risk of hospitalization than Group 1, and patients who are less than 50 and have received a booster have only a very slight increase in risk. Combined, CEV groups 1 and 2 have 2.5-4 times the likelihood of hospitalization than the general population of the same vaccine status and age category.

Vaccination Status
Vaccination greatly reduces the risk of hospitalization from infection with the Omicron variant. Vaccination with 2 doses reduces the probability of hospitalization by a factor of 3; a third dose is associated with a 6.4-fold reduction of hospitalization. A fourth dose (second booster) addresses waning of immunity in those who are less likely to mount a strong immune response; although long-term data is lacking, waning protection against hospitalization has been seen after 4-6 months. In the lower-risk general population, a 3rd or 4th vaccine doses do not lead to a large absolute change in the risk of hospitalization, whereas in higher-risk groups, this change is significant enough that a 2-dose series is considered sub-optimal, especially since patients who have not received a booster have likely received second doses more than 6 months ago. There are currently not enough data support different recommendations based on vaccine timing; however, the CTC and BCCDC are actively monitoring the impact of waning on hospitalizations from Omicron.

Age
Age is a well-known single most powerful predictor of hospitalization and death; an 80-year-old patient with COVID-19 has 28 times greater odds of requiring hospitalization than a patient who is 18. Patients over 70, even if vaccinated, still significant hospitalization rates despite the decreased likelihood in the Omicron wave, whereas individuals younger than 50 have a hospitalization rate of <1 - 2.5%, even if unvaccinated. Age is also a confounding factor for chronic conditions/co-morbidities, which further increase the risk of hospitalization.

Number of chronic conditions/co-morbidities
Completely healthy individuals, even if unvaccinated, have a low risk of hospitalization except perhaps for those with very advanced age. The number of chronic conditions, as opposed to the type of co-morbidity, is a strong predictor of hospitalization across all age groups. Those with three or more chronic conditions need to be specifically considered as even 2 or 3 vaccine doses does not fully mitigate the risk of multi-morbid elderly patients. Most common co-morbidities increase the odds of hospitalization 2 to 3-fold; the type of co-morbidity does not seem to matter a great deal if not included in the CEV criteria. For example, those with substance use disorder have a similar increase in risk to those with non-insulin requiring diabetes.

Testing
Patients who are eligible for treatment are those who test positive for COVID-19 via a Polymerase Chain Reaction (PCR) or Rapid Antigen Test (RAT) test. During early days of symptom onset, PCR is the preferred diagnostic test due to its increased sensitivity (standard PCR or rapid molecular tests).

New testing guidelines issued by the BCCDC offer PCR testing to all those who may be candidates for treatment as they were developed in collaboration with the CTC. Such patients should be encouraged to get tested if they are symptomatic. In cases of limited access to timely PCR results, if a RAT is provided at the testing centre or if a patient performs a RAT from their own supply, positive results will be accepted for treatment considerations. A positive RAT test does not require confirmation by PCR to proceed with treatment.

Testing information is update regularly at [http://www.bccdc.ca/health-info/diseases-conditions/covid-19/testing](http://www.bccdc.ca/health-info/diseases-conditions/covid-19/testing)

### Practical Considerations for assessing validity of a rapid antigen test:

- Ensure the test was done recently and that it is positive
- For patients who test positive via a RAT, verify how the test was done and how did the positive result present. Patients can be asked to show a photo or the test itself to ensure therapy is not provided with the intention of diversion or medication stockpiling
- Consider the possibility of false positive RAT results in those without a positive lab-based test result. Potential causes for false positive results may include other respiratory viruses and reactions with certain foods or liquids.
- Consider organising lab-based testing for individuals with only a positive RAT result if there are concerns regarding the validity of the result and it is feasible to obtain the results during the treatment window.
- The pre-test likelihood of COVID-19 infection may be influenced by known contact with COVID-19 cases, symptoms compatible with COVID-19, and the prevalence of disease in the community. The table below provides the positive predictive value for a test with 98% specificity and 75% sensitivity (similar to most RATs currently available) for a range of pre-test probability of infection from 0.01 to 0.15.

<table>
<thead>
<tr>
<th>Pre-test probability of infection</th>
<th>Positive Predictive Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01</td>
<td>0.27</td>
</tr>
<tr>
<td>0.05</td>
<td>0.66</td>
</tr>
<tr>
<td>0.1</td>
<td>0.81</td>
</tr>
<tr>
<td>0.15</td>
<td>0.87</td>
</tr>
</tbody>
</table>

- Patients given a gargle test will have a QR code to register the positive test; encourage that they follow the steps outlined on the testing package if they have not already done so
- Epidemiologically linked cases (e.g., household contacts of those who test positive) who have not been confirmed via COVID-19 testing should not be offered treatment. Encourage such patients to make an appointment for testing if they qualify

### Symptoms and Symptom Progression
Patients offered treatment should be **appreciably symptomatic from COVID 19.** Patients who are **moderately ill,** i.e., showing evidence of lower respiratory disease during clinical assessment or imaging and who have decreased oxygen saturation (but still ≥94% on room air) are most likely to progress to severe illness requiring supplemental oxygen and can be offered therapy.

**Mild illness,** i.e., individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have, dyspnea, increased work of breathing or abnormal chest imaging can progress to severe illness, especially if those symptoms are profound, or exist in combination. Flu-like symptoms such as fever and diffuse myalgia are indicative of systemic illness and have been shown to be associated with higher risk of illness progression. **Great deal of case-by-case clinical judgement is required to discern whether mild symptoms warrant treatment. In equivocal cases, a 24-48 hour follow-up period is reasonable, if still within the treatment window.**

**Illness trajectory** is a useful in establishing progression of COVID-19. Patients who are visibly deteriorating are more likely to become severely ill. **Treatment is unlikely to benefit those who are mildly ill who are clearly improving on their own. Treatment should not be given to asymptomatic or minimally symptomatic patients.**

### Symptom Window

Symptom windows vary with each therapeutic agent and follow study inclusion criteria. Remdesivir (and sotrovimab if used in extenuating circumstances) **should be given within 7 days of symptom onset** whereas for oral antivirals **should be given within 5 days. It is appropriate to allow the addition of adequate time for drug delivery of medication for those living in remote and rural communities.** Patients who are in the ≥5% risk category who have passed the 5-day but are within the 7-day treatment window and would be referred for remdesivir solely based on its longer treatment window can be prescribed nitmatrelvir/ritonavir within 7 days of symptom onset.

In clinical trials, viral loads decreased from the nasopharynx by 1000’s-fold during treatment regardless of the receipt of an active treatment or placebo. Furthermore, most patients produced their own antibodies shortly after becoming infected and exogenous antibodies do not confer additional benefit. **There is little clinical rationale for extending the treatment window past 7 days.**

Patients who have had prolonged symptoms or more or protracted illness despite recently testing positive for COVID-19 may require a clinical assessment of the illness trajectory to rule out other causes responsible for their symptoms. Patients are encouraged to get tested as soon as possible after COVID symptoms appear to avoid conflating persistent symptoms with COVID-19 infection.

### Hospitalized Patients

Patients who are hospitalized for other reasons and are mildly-moderately ill with COVID-19 can be considered for treatment if they meet the eligibility criteria. Many patients admitted to hospital are incidentally diagnosed or are part of nosocomial outbreaks and are offered testing with very low thresholds.
that often does not warrant treatment. **Patients who are offered treatment in hospital need to be appreciably symptomatic and benefit from careful case-by-case assessment by an expert.**

Hospitalized patients, if they meet treatment criteria, can more easily receive intravenous therapy than outpatients. They may also be more prone to drug-drug interactions or have contraindications for nirmatrelvir/ritonavir such as renal dysfunction. Remdesivir, due to its multiple-day IV dosing, may also be more feasible in this setting. *The ultimate choice of therapeutic agent in-hospital depends on drug scarcity, drug-drug interactions and contraindications and needs to be determined on a case-by-case basis at the time of treatment selection.*

### Contraindications

**Nirmatrelvir/ritonavir** should not be used in end-stage liver disease (Child-Pugh C), severe renal disease (eGFR < 30ml/min). In patients with hepatitis B and C, or HIV infection regardless of treatment status may benefit from Specialist Consultation (e.g., Infectious Diseases, HIV Specialist), but treatment should not be withheld or delayed due to these conditions. Many drug-drug interactions contraindicate the co-administration of nirmatrelvir-ritonavir, but some can be held or managed. Contraindicated drugs include amiodarone, apixaban and rivaroxaban, certain antipsychotics like clozapine, midazolam and triazolam, as well as illicit drugs especially fentanyl and methamphetamine (see **Practice Tool #3: Drug Interactions and Contraindications**). Patients with hypersensitivity to ritonavir or other protease inhibitors should not be prescribed nirmatrelvir/ritonavir. **Drug interactions must be verified and a management plan in place before prescribing.** If drug-drug interactions pose safety concerns, treatment can be forgone, especially in those who have a very slightly increased risk of hospitalization (3-4%).

**Remdesivir** is contraindicated in those with demonstrated hypersensitivity to the product or any of its ingredients. While the monograph states that there are no data to support its use in eGFR < 30ml/min (due to the cyclodextrin component), numerous studies, including a yet-to-be published RCT of >1000 patients conducted by Gilead support its safety in this population. (For a full operational review of remdesivir, including renal dosing, consult your health authority to obtain the CTC and CTRAWG memo regarding remdesivir operationalization). Remdesivir should not be used in patients with ALT ≥5 times the ULN. The pharmacokinetics and safety of remdesivir in hepatic impairment have not been evaluated; expert consultation is recommended. While pregnancy and paediatric considerations are not part of the Canadian labelling, remdesivir has approval for children age ≥ 12 years weighing ≥ 40kgs in the US and has been given to pregnant women in independent studies. Specialty consultation is recommended for these populations.

**Sotrovimab** is known to cause hypersensitivity reactions and infusion reactions, although they are rare. Sotrovimab is contraindicated in those who are hypersensitive to this drug or to any ingredient in the formulation: if reactions develop during the 1-hour infusion, the infusion should be stopped.

**Molnupiravir** contraindications are not well articulated as the Canadian Monograph has not been published due to lack of Health Canada approval. This will be updated when known. Based on FDA data, molnupiravir will be contraindicated in pregnancy, breastfeeding, in those trying to conceive and in pediatrics.

### Pregnancy, Breastfeeding and Pre-Conception
Pregnancy is a risk factor for hospitalization and pregnant women have 3 times the odds of hospitalization in BC compared to age-matched non-pregnant women. Vaccination in this population is also lower than age-matched cohorts. However, pregnant persons are young, and most do not have co-morbidities; as such the absolute risk of hospitalization in a pregnant person is still below the treatment threshold.

Currently available therapies have not been evaluated in pregnancy or breastfeeding. The Reproductive Infectious Disease and Maternal Fetal Medicine COVID-19 working group would potentially consider remdesivir for use in pregnant or breastfeeding women if they otherwise meet the above-mentioned treatment criteria (e.g., immunocompromise or unvaccinated). Nirmatrelvir/ritonavir may also be acceptable due to familiarity and comfort with prescribing protease inhibitors to this population. Sotrovimab is considered safe; however, this needs to be balanced against a potential loss of activity. Animal studies have not demonstrated a significant risk to the fetus from all three drugs. Prescribers may consult Reproductive Infectious Disease on call at BCCW if prescribing COVID-19 therapy, especially nirmatrelvir/ritonavir in pregnancy in high-risk women, or for advice during breastfeeding.

Molnupiravir has been found to negatively impact fertility, embryonic development and pregnancy outcomes in animal studies and is contraindicated in pregnancy or in those with childbearing potential unable or unwilling to use protection.

It is unknown whether COVID-19 therapies impact fertility. Patients are encouraged to use protection while taking these medications. Those who are on oral contraceptives should use a back-up method when taking nirmatrelvir/r due to drug interactions leading to lower plasma levels of estrogen, decreasing its efficacy in preventing pregnancy.

### Pediatrics

Nirmatrelvir/ritonavir is not approved for pediatric use, and remdesivir is not approved in children with mild-moderate COVID-19 in Canada (but is in the US). Sotrovimab has pediatric approval but has significant loss of neutralization capacity against BA.2 and may not be appropriate in very high-risk children. The following statement regarding pediatric therapy has been developed in collaboration with experts from BCCH:

Pediatric patients with immune compromise are generally considered to be at lower risk of developing severe COVID-19 illness and requiring hospitalizations compared to adults with immune compromise. Risk of severe COVID disease in immunocompromised children appears to be related to underlying comorbidities rather than immune suppression itself. Immunocompromised children may present with atypical signs and symptoms of COVID-19 that can fluctuate rapidly between being asymptomatic to having mild to moderate symptoms and vice versa. Information on COVID-19 vaccine immunogenicity in children with immune compromise is currently limited.

In consultation with pediatric infectious diseases and appropriate subspecialist, treatment with should be considered for COVID-19 positive immunosuppressed children 12 years of older and minimum 40kg with mild to moderate COVID-19 symptoms not requiring hospitalization who are:

- Solid organ transplant recipients
- Hematopoietic stem cell/bone marrow transplant recipients within the past 2 years and/or are currently receiving immunosuppression
- Immunosuppressed due to primary immunodeficiency or due to iatrogenic causes
- Have been otherwise classified as extremely clinically vulnerable due to immunosuppression (CEV 1 or 2)

AND

- Have another major chronic condition/comorbidity putting them at risk of severe COVID-19, especially significant lung disease (e.g., lung transplant recipients, lung GVHD, obstructive lung disease). Being unvaccinated or partially vaccinated is a risk factor for severe COVID-19 disease, bearing in mind that some fully vaccinated children with immune compromise also may not generate vaccine immune response.

The choice of agent will depend on an individualized risk-benefit assessments of the available therapies. Children with immune compromise and no major comorbidities are unlikely to develop severe COVID-19 disease. The benefit of providing treatment in these cases is likely very small.

Ultimately, decisions around the use of remdesivir or sotrovimab should be made on a case-by-case basis, weighing lack of RCT-level data in children, off-label use and the potential benefit of treatment. Clinicians are encouraged to discuss cases with the Pediatric Infectious Diseases physician on call at BC Children’s hospital. If IV therapy is being pursued, infusions can be arranged at BC Children’s hospital through the patient’s BC Children’s Main Responsible Physician/Service, as per hospital protocol. For those patients outside the vicinity of BC Children’s hospital, arrangements will need to be made through the local health authority at an available infusion site.

**Drug-Drug Interactions**

Nirmatrelvir and ritonavir have significant drug-drug interactions, many of which contraindicate its use. Nirmatrelvir and ritonavir are potent inhibitors of CYP 3A4 and increase the concentration of many drugs metabolized by this enzyme. Nirmatrelvir/ritonavir is also contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.

Some drug-drug interactions can be managed. For a comprehensive list of drug-drug interactions and management strategies see [Practice Tool #3: Drug Interactions and Contraindications](#).

The most comprehensive resource for DDI assessment with nirmatrelvir/ritonavir is available from the University of Liverpool at [https://www.covid19-druginteractions.org/checker](https://www.covid19-druginteractions.org/checker).

Remdesivir has no DDIs that contraindicate its treatment, except for chloroquine and hydroxychloroquine which may reduce its antiviral efficacy. Strong CYP 3A4 inducers (e.g., phenytoin, rifampin, carbamazepine) may decrease the serum level of remdesivir but the clinical relevance of this interaction is not known.

Sotrovimab possesses no significant drug-drug interactions.
Dosing

Nirmatrelvir/ritonavir is dosed at nirmatrelvir/ritonavir 300/100mg PO BID x 5 days for those with eGFR > 60 ml/min. It is supplied as a pre-packaged kit containing both products: 2 tablets of nirmatrelvir 150mg and 1 tablet of ritonavir 100mg per dose. The patient takes 3 tablets per dose, for a total of 30 tablets during the treatment course.

Patients with an eGFR of 30-60 ml/min should take nirmatrelvir/ritonavir 150/100mg PO BID x 5 days, or one nirmatrelvir 150mg tablet and one ritonavir 100mg tablet per dose. The second nirmatrelvir tablet should be removed from the kit from each dose by the dispensing pharmacist for the patient to avoid confusion and diversion.

Remdesivir for mild-moderate COVID-19 in patients with an eGFR ≥ 30ml/min is dosed with a loading dose of 200mg IV on day 1, followed by 100mg IV on days 2 and 3. This dose differs from its dose in the monograph for severe COVID-19 infection. Each vial contains remdesivir 100mg for a total of 4 vials per full treatment course. There is no dose adjustment required for obesity or mild-moderate renal or liver impairment. Patients with renal disease who have an eGFR <30 ml/min can safely receive standard dosing; however based on known PK and limited clinical data, renal and COVID experts in BC agree that a renally adjusted dosing can be used to optimize operationalizing administration of infusions. Such patients can receive 200mg IV on day 1, followed by 100mg IV 48 hours later. Patients on hemodialysis can receive their dose during dialysis, and can receive their second dose 48-72 hours later depending on their hemodialysis schedule.

Sotrovimab is dosed at 500mg IV x 1 dose infused over 60 minutes. The manufacturer is currently evaluating the in-vivo efficacy of a 1000mg dose against the BA.2 variant, as such dose is likely to overcome the reduced neutralization capacity. A regulatory decision regarding the approval of this dose is forthcoming. There are no dose adjustments required for obesity or mild-moderate renal or liver impairment. The drug is not recommended for IM use.

Patient Location

Patients with mild to moderate COVID-19 are usually outpatients recovering at home. However, many patients hospitalized for non-COVID reasons can also be offered treatment (see Hospitalized Patients above). Patients in Long-Term Care are eligible for treatment if they meet criteria, with an understanding that IV therapeutics cannot be administered easily in LTC settings. Patients may also be offered treatment in Emergency Departments. This guidance is not specific to any particular patient location.

This guide does not specify priority for patients in remote or rural areas; CTRAWG (a committee responsible for equitable distribution of scarce drug resources) may prioritize different geographical areas if needed. Additional time added to the patient’s symptom window is clinically acceptable for drug transport to remote and rural areas.
**Clinical Judgement**

This guide should not replace clinical judgement. Patients who are technically eligible for treatment may not be good candidates due to clinical status, goals of care, or willingness to provide consent for treatment. These factors need to be considered with each patient assessment.

The current eligibility criteria are conservative, and the absolute risk of hospitalization depicted in thermal maps is overestimated due to a testing bias. There should be very few patients who have a risk of <3% who should be offered treatment and are not captured in this guide; however, such decisions are again deferred to the treating clinician.

<table>
<thead>
<tr>
<th>SUPPORTING EVIDENCE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Summary of Trials</th>
</tr>
</thead>
</table>

**Nirmatrelvir/ritonavir**

Nirmatrelvir is a protease inhibitor with a 2-hour half-life; it is co-administered with ritonavir to allow BID dosing. Nirmatrelvir/r has been evaluated in a phase 3 clinical trial EPIC-HR, which was published in the NEJM in February 2022.

EPIC-HR was a randomized double-blind placebo-controlled trial:
- 2246 adult outpatients with mild-moderate COVID-19 who were enrolled
- Patients had to be within 5 days or less of symptom onset
- Patients included had to be unvaccinated and at increased risk of developing severe disease, defined as age 60 or older or having a chronic condition such as diabetes, heart condition or chronic kidney disease
- The mean age of patients in the trial was 47; most had a single co-morbidity, the most common of which was smoking
- Patients were randomized in a 1:1 fashion to receive nirmatrelvir/ritonavir or placebo
- The primary endpoint was COVID-19-related hospitalization (not all-cause), or death from any cause.
- The primary endpoint occurred in 66/1064 (6.3%) patients given placebo vs. 8/1039 (0.8%) patients randomized to active treatment for a relative risk reduction of 88%, an absolute risk reduction of 5.5% and an NNT of 18.
- A high-risk subgroup of ~200 patients was analysed (those over 65 with more risk factors). This group, which is similar to the patients prioritized for treatment in this guide, experienced a nearly 15% absolute risk reduction in COVID-19 hospitalization (16.3% vs. 1%, p<0.001).
- Side effects that were drug-related included diarrhea, nausea, dysgeusia, muscle aches and hypertension. The rate of drug related ADRs was 7.8% in the treatment arm vs. 3.8% in the placebo arm, for a NNH with one side effect of 25.

Based on these data, nirmatrelvir/ritonavir is given a AIIa recommendation by the NIH and a conditional recommendation by the IDSA to suggest treatment over no treatment.

**Remdesivir**
Remdesivir is an intravenous antiviral initially evaluated in severely ill inpatients with COVID-19 requiring oxygen support in a landmark trial ACTT-1. It was approved by Health Canada for this indication, and some nationally procured supply remains unused due to subsequent data showing its lack of impact on meaningful outcomes in the severely ill population.

In December 2021, a trial called PINETREE was published:
- The trial evaluated remdesivir in 562 mildly-moderately ill outpatients
- Patients were randomized to receive remdesivir 200mg IV on day 1, followed by 100mg on days 2 and 3 or placebo and evaluated in a double-blind fashion
- Patients were included if they presented within the previous 7 days and who had at least one risk factor for disease progression (age ≥60 years, obesity, or certain coexisting medical conditions)
- The trial was stopped when only 45% of the planned population was recruited due to widespread use of vaccination and the availability of proven treatments making randomization to placebo ethically challenging
- The primary outcome was COVID-19–related hospitalization or death from any cause
- 2 of 279 patients (0.7%) in the remdesivir group and in 15/283 (5.3%) in the placebo group met the primary endpoint, p=0.008.
- This equated to an 87% relative risk reduction, a 4.6% ARR and a NNT of 22, which is slightly higher than nirmatrelvir/ritonavir or sotrovimab (17 and 20, respectively).
- A total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a COVID-19–related medically attended visit by day 28 an no patients died by day 28.
- Remdesivir was generally well tolerated; transaminases may need to be monitored in patients with baseline elevations of liver enzymes. Remdesivir has been given to patients with renal disease with and without dose adjustments; however, it was not evaluated in this trial and this population is excluded from Canadian labelling.

Remdesivir has the advantage of having few drug interactions while maintain comparable risk reductions to nirmatrelvir/ritonavir. However, the 3-day IV dosing regimen is difficult to administer, and the CTC recommends that it be used if nirmatrelvir/ritonavir cannot be prescribed only in the highest-risk population (patients with a ≥ 5% risk of hospitalization from Omicron). The NIH recommends remdesivir as an alternative to nirmatrelvir/ritonavir with a Grade BII rating. The IDSA suggests remdesivir with a conditional rating and low certainty evidence.

**Sotrovimab:**

Sotrovimab has been evaluated in a single peer-reviewed, double blind, randomized-placebo controlled trial (COMET-ICE):
- 1057 patients with mild symptoms of COVID-19 and at least one risk factor for disease progression were included
- Patients were randomized to receive a single dose of sotrovimab 500mg IV compared to placebo
- Most patients were younger (<50) and had one single chronic condition, with obesity being the most prevalent comorbidity
- The primary endpoint was a composite outcome of all-cause hospitalization for >24 hours or death within 29 days of the receipt of the infusion
- Out of the 528 patients who received sotrovimab, 6 met the primary endpoint of hospitalization or death vs. 30 of the 529 who received placebo (1% vs. 6%; p<0.001; ARR=5%, NNT=20). There were only 2 deaths observed (placebo arm); the primary endpoint was driven entirely by hospitalizations.
Hospitalizations were consistent with progressive COVID-19 requiring oxygen support and hospital-level care; only 1 hospitalization was not COVID-related.

Secondary outcome results demonstrated that sotrovimab significantly reduced progression to severe/critical respiratory COVID-19 compared with placebo (1 vs. 5% p=0.002).

Sotrovimab did not reduce length of stay or ICU-bed-days.

The proportion of patients reporting adverse events was similar between treatment groups; sotrovimab was well tolerated, and no safety concerns were identified; 6 patients in each placebo and sotrovimab groups experienced mild to moderate infusion reactions.

The COMET-ICE trial was well conducted, with a high degree of generalizability posing no major concerns during critical appraisal. Sotrovimab is given a positive conditional recommendation by the Infectious Diseases Society of America and a Grade AIIa recommendations supporting its use by the NIH, but those are likely to change with the emergence of the BA.2 variant.

**BA.2 Variant:** Recently, however, in-vitro studies against viral-like particles (VLPs) show that sotrovimab has reduced binding against the BA.2 variant of Omicron. This VoC has become the predominant variant in BC since March 2022. The reduction in neutralization is 16-31-fold lower than against non-BA.2 variants, and up to 48-fold lower in animal studies using authentic Omicron virus. Furthermore, according to the manufacturer, when an average lung penetration of 25% seen in PK studies is considered, a 500mg dose achieves the effective concentration (EC90) for only 15 days (and even fewer if more conservative lung penetration levels are used). While so far clinical efficacy drops have not been observed, the FDA has revoked the emergency use authorization based on an abundance of caution. The CTC is actively monitoring the impact of BA.2 on sotrovimab outcomes in BC; however, as the totality of evidence for other therapies is stronger, sotorovimab is currently the last line drug in the armamentarium against COVID-19. The CTC is also awaiting the Health Canada decision pertaining to the 1000mg dose.

**Molnupiravir**

Molnupiravir is a nucleotide analogue which when incorporated into viral RNA causes base-pair mismatch leading to mutations and viral catastrophe. The mechanism of action of the drug has been scrutinized by regulators for the theoretical fear of promoting emergence of variants of concern due to promoting mutations as well as reproductive safety.

Molnupiravir was evaluated by a randomized, double blind controlled trial called MOVe-Out:

- 1408 outpatients with mild-moderate COVID-19 presenting within 5 days of symptom onset were assigned in a 1:1 fashion to receive molnupiravir 800mg PO BID x 5 days or placebo.

- The primary endpoint was all cause hospitalization or mortality within 29 days.

- The trial stopped when a pre-planned interim analysis revealed that it met the primary endpoint with a 50% relative risk reduction and a p value (set at p<0.0092 to allow for alpha spending) which was statistically significant.

- In that analysis, 28/385 (7.3%) of patients on active treatment experienced the primary outcome, vs. 53/377 (14.1%) who received placebo, for an ARR of 6.8%. Trial recruitment stopped, but there were still another ~600 patient who were undergoing 29-day follow-up.
In the final analysis published in December 2021, it was discovered that the ARR for the entire trial population declined to just 3%, with 6.8% (48/709) patients in the treatment arm experiencing the primary outcome vs. 9.7% (68/699) in the placebo arm.

This difference, if the same pre-specified p-value from the interim analysis is applied, is not statistically significant (p=0.0218). A time-to-event analysis depicted by a Kaplan-Meier curve as also not statistically significant.

Data from the FDA reveal that during the second half of the study, the event rate was numerically higher in the molnupiravir arm than the placebo arm (20 vs. 15 events, respectively).

The primary outcome appeared to be driven by very high event rates (>20%) that were apparent in countries like Brazil, whereas higher income countries like the US had no appreciable reductions in hospitalization resulting from the effects of the drug.

Molnupiravir carries the advantage of having few or no drug-drug interactions and is not impacted by renal or liver disease. Such details, however, are not currently available as the drug is undergoing evaluation by Health Canada and the monograph has not been issued in Canada.

**Repurposed Therapies**

The CTC has evaluated various other therapies that are not routinely recommended, including colchicine and the abovementioned SSRI fluvoxamine.

In short, Colchicine was evaluated at 0.6 mg PO BID x 3 days, then 0.6 mg daily x 27 days in a single large Canadian RCT (COLCORONA) and demonstrated a reduction in progression of COVID-19 and hospitalization in a sub-group of patients with PCR confirmed COVID-19. The trial was stopped early; due to decreased power leading to the low certainty of its results, as well as a higher risk of adverse events (diarrhea and blood clots) guidelines (WHO, NIH) do not recommend colchicine. The CTC states that if colchicine is used outside of clinical trials, full disclosure of risks and benefits with consideration of patient values are necessary. Overall, the uptake of the drug in BC has been very low to none.

Fluvoxamine was evaluated at 100 mg PO BID x 14 days in a Brazilian RCT and shown to reduce emergency room visits > 6 hours, a surrogate endpoint for hospitalizations. It has not demonstrated a benefit in reducing actual hospitalizations from COVID-19, length of stay or mortality. For every 12 trial participants, one additional patient stopped fluvoxamine prematurely. Due to low generalizability from a very high event rate, as well as lack of robust safety data, guidelines (e.g., IDSA) do not recommend the use of fluvoxamine outside of clinical trials. A Canadian fluvoxamine study stopped enrolment due to futility. The CTC states that if fluvoxamine is used outside of clinical trials, full disclosure of risks and benefits with consideration of patient values are necessary. There were also additional concerns posed about the lack of full safety evaluation with this dose. The recommended starting dose in patients over 55 years old is 25mg daily, whereas the trial’s dosing is 8 times that dose. As fluvoxamine can cause a variety of side effects such as hypotension, dizziness, falls, QT prolongation and GI effects, the safety of this regimen deserves further study before the drug can be routinely used for treating COVID-19.

Five trials have evaluated inhaled steroids for the symptomatic relief of COVID-19 manifestations such as shortness of breath and cough, showing that treatment with inhaled steroids reduces symptoms and may reduce the need for hospitalization (although the latter has not been consistently demonstrated and has
thus far been a secondary endpoint of most trials). Due to familiarity and safety, inhaled budesonide 800 μg twice daily or ciclesonide 320 μg twice for 14 days may be considered on a case-by-case basis in adults with lower respiratory tract symptoms of COVID-19 aged 65 and over or aged 50 and over with underlying health conditions and within 14 days of symptom onset, acknowledging the limitations of these trials. There is no evidence to combine inhaled steroids with nirmatrelvir/ritonavir or remdesivir; some inhaled steroids interact with nirmatrelvir/ritonavir.

References: